Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Biotechnology_Proteomics

Anaphore

Parents

*Investors’ bet they can create genetically engineered protein drugs with greater capability to bind with targets than today’s antibodies
*Quite a few companies have been sprouting up and raising cash in the last couple years with similar notions of developing “bio-superiors” or “bio-betters.” (2010)
2010: Anaphore Snags $110M Deal With Mitsubishi Tanabe to Make Drugs for Immune Disorders (2010)
CEO Kathy Bowdish, Anaphore (2010)
Founded 2007
Has raised a total of $38 million in venture capital from 5AM Ventures, Versant Ventures, Apposite Capital, GlaxoSmithKline’s SR One venture group, Merck Serono, and Aravis Venture Associate (2010)
San Diego, California
The Atrimer technology platform brings extraordinary diversity and specificity to drug discovery.
The trivalent structure of Atrimers affords three binding regions, each containing loops of amino-acid sequences that can be programmed to yield a drug candidate that binds to its target with high potency and exquisite specificity. The trivalent structur